01 - ACCELERATING DISCOVERY

Redefining the Speed of Drug Discovery

Artemis Therapeutics was founded by Dr. Artem Cherkasov and Dr. Mads Daugaard to harness more than three decades of pioneering research in molecular modelling, machine learning, and functional drug validation.

At the heart of Artemis is DeepDocking™, an AI-accelerated virtual screening platform pioneered by Dr. Cherkasov. This technology has fundamentally transformed structure-based drug discovery, enabling up to 6,000-fold acceleration in virtual screening compared with traditional methods.

What once required years of computational effort can now be accomplished in days.

02 - PROVEN PERFORMANCE

A Discovery Platform with Real-World Results

Artemis builds on a research platform with demonstrated scientific and commercial achievements.

acceleration of virtual screening

compounds screened in 19 days

drug candidates licensed to pharmaceutical companies

03 - NEXT-GENERATION TECHNOLOGY

Beyond DeepDocking™

DeepDocking-Lightning™

Enables an additional 20–100× acceleration compared with the original DeepDocking™ platform, dramatically expanding screening throughput and reducing time to insight.

DeepDocking-Ultra™

A next-generation AI platform designed to enable structure-based drug discovery at genome-wide scale, expanding target coverage and enabling systematic, scalable discovery across vast biological landscapes.

Together, these technologies form an integrated computational discovery platform, from large-scale virtual screening to candidate nomination.

04 – OUR BUSINESS MODEL

An Asset-Driven Approach to Biopharma

Artemis operates as an asset-driven biopharma company, using its proprietary platform to generate and advance its own drug candidates. This model enables Artemis to capture the full upside of the assets it creates, translating computational breakthroughs into clinical and commercial value.

Artificial intelligence is the engine. Drug candidates are the outcome. Patients are the purpose.

What will we discover next?

If you are interested in partnering, investing, or exploring scientific collaboration, we welcome the conversation.

CONTACT ARTEMIS